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Abstract
Background: The number of people surviving colorectal cancer has doubled in recent years. While much of the
literature suggests that most people return to near pre-diagnosis status following surgery for colorectal cancer, this
literature has largely focused on physical side effects. Longitudinal studies in colorectal cancer have either been
small scale or taken a narrow focus on recovery after surgery. There is a need for a comprehensive, long-term
study exploring all aspects of health and wellbeing in colorectal cancer patients. The aim of this study is to
establish the natural history of health and wellbeing in people who have been treated for colorectal cancer. People
have different dispositions, supports and resources, likely resulting in individual differences in restoration of health
and wellbeing. The protocol described in this paper is of a study which will identify who is most at risk of
problems, assess how quickly people return to a state of subjective health and wellbeing, and will measure factors
which influence the course of recovery.
Methods/design: This is a prospective, longitudinal cohort study following 1000 people with colorectal cancer
over a period of two years, recruiting from 30 NHS cancer treatment centres across the UK. Questionnaires will be
administered prior to surgery, and 3, 9, 15 and 24 months after surgery, with the potential to return to this cohort
to explore on-going issues related to recovery after cancer.
Discussion: Outcomes will help inform health care providers about what helps or hinders rapid and effective
recovery from cancer, and identify areas for intervention development to aid this process. Once established the
cohort can be followed up for longer periods and be approached to participate in related projects as appropriate
and subject to funding.
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Background
Around two million people are living with or beyond
cancer in the UK and this figure is rising by more than
3% per year [1]. Whilst increasing survival rates are to
be celebrated, the experiences and needs of those who
have completed their primary cancer treatment have
been relatively neglected [2,3]. Health professionals may
be unaware of who is struggling with problems [4]. The
best ways to assess problems people experience or
which interventions are effective in helping relieve or
prevent problems following primary treatment are lar-
gely unknown [2]. With rising numbers of survivors the
need to understand problems experienced following
treatment, how they can be resolved, ways in which peo-
ple manage their own problems and how health profes-
sionals can support self-management are becoming
increasingly important for service planners and health
policy makers.
The range of problems faced by cancer survivors and
how they change and resolve over time are not well
understood. No published research has systematically
studied the health and wellbeing of cancer survivors over
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the years following primary treatment [2]. US and Eur-
opean evidence demonstrates that cancer survivors fare
less well than healthy individuals in terms of health and
wellbeing [5,6], and recent UK evidence has shown that
cancer survivors have similar scores to people with long
term conditions on a range of measures including psy-
chological wellbeing and physical functioning [7]. Cancer
survivors have also been shown to access more health
services than healthy counterparts [5,6] These studies
cannot reveal the continuing care needs of individuals
and whether these are met through current health care
provision [2].
Failing to provide appropriate long term support across
the spectrum of problems faced following primary treat-
ment may have negative consequences for health and well-
being of the growing number of survivors [4] and may
prevent them from returning to productive lives, both
socially and economically [2]. Evidence suggests that most
survivors manage to live well with problems associated
with cancer and its treatment; however, a substantial min-
ority (around one third) consistently report difficulties in
the long term [8]. Early intervention could help alleviate
some longer term problems. For example, predicting
which people are most at risk of developing problems
could reduce avoidable hospital admissions [9]. In order to
know how to intervene, first we must understand how
health and wellbeing is restored over time (or not) and
which risk and protective factors indicate who is most
likely to need support and when.
Survivors of colorectal cancer form the largest group of
cancer survivors affecting men and women [10]. Incidence
is high (it is the third most common cancer) and survival
rates have doubled in recent years with around 250,000
UK survivors [11]. Survival rates are around 52% irrespec-
tive of extent of disease at cancer diagnosis, with little
decline in survival rates beyond 5 years, at which point
survivors are deemed by convention to be cured [12]. As
well as being a large group of survivors, colorectal cancer
is treated using all the main treatment modalities of sur-
gery, radiotherapy and chemotherapy, and so colorectal
cancer patients are likely to experience many of the pro-
blems associated with cancer therapy. Available studies
have consistently found that people with colorectal cancer
are at risk of experiencing poor quality of life [13-18]. The
cancer experience and ongoing symptoms have an impact
on physical functioning and carrying out daily activities
which may have long term consequences for the resump-
tion of normal everyday life, such as return to work and
finances [14,19]. Symptoms such as fatigue, psychological
distress, sexual dysfunction and altered bowel habits may
be long lasting [13,14,18,20]. These persistent difficulties
alongside continued feelings of uncertainty and concerns
for the future [21] not only have implications for an indivi-
dual’s health but also their sense of subjective wellbeing.
While much of the literature suggests that most col-
orectal cancer patients return to near pre-diagnosis
status following surgery, Taylor et al [22] argue this lit-
erature has largely focused on physical side effects
rather than recovery as a total human response,
including emotional, spiritual and social factors, which
may be equally important in the restoration of health
and wellbeing [22]. Much of the work on quality of life
in colorectal cancer is from cross-sectional studies
[18]. Some longitudinal studies have been conducted
in colorectal cancer, such as those by [23] and Taylor
et al [22]. However, these have either been small scale
or taken a narrow focus on recovery following cancer,
such as psychological status or symptom distress
[22,23]. A comprehensive, long term study exploring a
comprehensive range of aspects of health and well-
being in colorectal cancer patients and following the
normal pattern of restoration of health and wellbeing
has not been conducted. This paper presents the pro-
tocol for such a study, funded by Macmillan Cancer
Support, to be conducted by the Macmillan Survivor-
ship Research Group in conjunction with the Univer-
sity of Southampton and the National Cancer Research
Network.
Foster and Fenlon [24] have developed a conceptual
model of recovery of health and wellbeing once cancer
treatment is finished, which recognises that social, phy-
sical and emotional factors all have an impact on recov-
ery (Figure 1). The central core of the model assumes
that people’s subjective sense of health and wellbeing
diminishes following the diagnosis and treatment of can-
cer and that this recovers over time. The extent to
which health and wellbeing are affected and the rapidity
with which they are restored will be affected by many
factors. These include the severity of the illness, its
treatment and subsequent impact on physical health;
and also pre-existing factors, such as the age, gender
and social status of the individual affected. The way in
which people cope with this and work to regain their
health will depend on internal factors, such as personal-
ity and self-efficacy to manage cancer related problems,
and external factors, such as the support they have
available to them. Our previous research suggests that
confidence is key to enabling people to manage pro-
blems following primary cancer treatment and that this
is important for recovery of health and wellbeing. This
model will inform the data collection in the current
study.
Study aims and objectives
Aim
The aim of the study is to establish the natural history
of the recovery of health and wellbeing in people who
have been treated for colorectal cancer.
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Objectives
The study objectives are to:
1. Plot the natural history of the recovery of health
and wellbeing following treatment for primary colorectal
cancer.
2. Investigate whether and how health needs change
over this period.
3. Explore factors that influence the restoration of
health and wellbeing and determine who is most at risk
of poor or protracted recovery.
4. Chart utilisation of health care services in this per-
iod and explore its relationship with recovery of health
and wellbeing.
5. Describe use of self-management techniques,
exploring characteristics which are related to use of self-
management behaviours and their relationship with
recovery of health and wellbeing.
Methods/Design
This is a prospective, longitudinal cohort study con-
ducted in colorectal cancer survivors following primary
surgery using a mailed questionnaire survey.
Study setting
Patients will be recruited from 30 NHS treatment centres
that conduct surgery for primary colorectal cancer
throughout the UK. These centres will be chosen from
those who express an interest through the National Can-
cer Research Network (NCRN). Centres will be selected
for their ability to recruit high numbers of patients at a
fast rate (around 2-3 per week) and able to complete
their research governance procedures within 4-6 weeks.
A further consideration is that centres should cover a
wide range of geographical locations and ethnically
diverse populations. We will also approach centres in
Scotland, Wales and Northern Ireland.
Participants
We will recruit 1000 patients with colorectal cancer
through their clinical teams prior to primary surgery.
Patients will be eligible for study inclusion if they: a) have
a diagnosis of colorectal cancer (Dukes A-C) b) have no
distant metastases c) are awaiting primary surgery (or
rarely, just had primary surgery, including emergency pri-
mary surgery) d) ≥ 18 years old e) have the ability to com-
plete questionnaires (Language line facilities will be
provided for those who require it). Prior diagnosis of can-
cer (other than non-melanomatous skin cancer or in situ
carcinoma cervix) is an exclusion criterion.
Eligible patients will be identified by a member of the
patient’s direct care team through the multidisciplinary
team meetings (MDT) at each participating centre. All eli-
gible patients will be allocated consecutive Research Num-
bers which will be documented on each site’s Eligible
Patient Log. The outcome for every eligible patient will be
recorded against this number. Potential outcomes will be
recruited, missed, declined, or recruited at a reduced con-
sent level (see below). Patients will be invited to participate
through an invitation from their medical consultant, which
will be sent with the appointment letter for the patient’s
primary surgery pre-assessment clinic visit. Patients will be
approached about study participation when attending their
pre-surgical assessment appointment. At this face to face
contact all eligible patients will be supplied with full study
information and given a minimum of 48 hours to consider
participation in the study. Study information will include
details of the CREW study team at Southampton; it will
emphasise the voluntary nature of participation and
patients’ right to withdraw consent, at any time, without
the need for explanation, and without their personal care
being affected. Patients who wish to join the study will be
asked to read, complete and sign a consent form, which
will be returned to and countersigned by the recruiting
Figure 1 Recovery of health and well-being in cancer survivorship [24].
Fenlon et al. BMC Health Services Research 2012, 12:90
http://www.biomedcentral.com/1472-6963/12/90
Page 3 of 8
research nurse and a copy filed in patients’ medical notes.
Those who consent to participate will be given a baseline
questionnaire which they can complete at an appropriate
clinic visit or at home, and return to the CREW study
team in a reply paid envelope. Patients who present as
acute admissions (e.g. with bowel obstruction) will be
approached by their direct care team following surgery.
This group will form a separate and comparable subset of
the cohort.
Consent will also be sought to inform a patient’s General
Practitioner (GP) of CREW study participation, including
consent to contact them throughout follow-up in order to
ensure inappropriate contact with a patient is avoided dur-
ing the course of the study (for instance if the patient has
moved, died or experienced a change in mental capacity).
Some patients may prefer not to complete question-
naires and in this case can opt to consent to allow data to
be collected about them for the purposes of the research.
As well as demographic details, routinely collected NHS
data relevant to their disease and treatment will be sup-
plied to the research team. Fully informed written con-
sent will be obtained for this reduced level of study
participation.
Outcome measures
The measures used will be informed by domains identi-
fied in our Model of Recovery (Figure 1). Not all mea-
sures will be used at each time point. QLACS will be the
primary outcome measure and will be included at each
time point. Other measures will be included at key times
in order to answer key questions (see Figure 2).
Problems experienced
• The cancer diagnosis and treatment are the proble-
matic event under consideration. Data will be col-
lected from medical records on stage, type and grade
of disease as well as treatment details of surgery,
radiotherapy, and chemotherapy.
• Symptom burden may also be considered part of the
problematic event and this will be measured using the
EORTC-QLQ-C30 (quality of life scale) and colorec-
tal subscale EORTC-QLQ-CR29 [25]. The EORTC
QLQ-C30 is a core quality of life questionnaire of 30
cancer specific items [26]. The EORTC QLQ-CR29
[25] is a colorectal cancer specific module, designed
to use with the core module, of 19 items addressing
gastrointestinal symptoms, pain and problems with
micturition. There are separate scales for the partici-
pants with or without a stoma and separate items
addressing sexual function for men and women. This
scale has been widely used and demonstrates validity
and reliability [27]. The Supportive Care Needs Sur-
vey (SCNS-SF34, Boyes et al 2009) will be used to
capture cancer patients perceived needs using 34
questions covering five domains (psychological,
health system and information, physical and daily liv-
ing, patient care and support and sexuality needs).
Scores are scales to range between 0 and 100, with
higher scores indicating a higher level of unmet
needs. Recent analysis suggests that the scale is reli-
able and valid when used with cancer patients [28].
Health and wellbeing
• The Quality of Life in Adult Cancer Survivors scale
(QLACS) [29] assesses quality of life in five areas sug-
gested by long-term survivors themselves as relevant
to their lives (financial problems, benefits of cancer,
appearance, distress related to recurrence and distress
related to the family), and seven additional areas that
are relevant but not limited to cancer (negative feel-
ings; positive feelings; cognitive problems; pain; sexual
interest; sexual function; energy/fatigue and social
avoidance). QLACS has been validated amongst cancer
survivors [29] and has good convergent validity with
other QoL measures (e.g. FACT & SF36). Part A will
be used at every time point in the cohort with Part B
being used at 15 months and 2 years as these questions
are more relevant to long term cancer survivors.
• The Personal Wellbeing Index (PWI) [30] consists
of seven items covering seven domains which repre-
sent a deconstruction of the global question “How
satisfied are you with your life as a whole?”[31].
Each item is scored on 0 to 100 with a mean taken
of all items, where a high score denotes high satis-
faction. A score of 70 represents a threshold for fail-
ure reduced wellbeing [32]. The PWI has been
found to be consistent for large populations with
normative data of 74.93 for a healthy population (SD
0.75). The PWI has good reliability (Cronbach’s
alpha between .70 and .85, and intra-class correla-
tion coefficient of 0.84 [33] and a high level of sensi-
tivity between different demographic groups [31].
The EQ-5D™ is a 5 item questionnaire assessing
aspects of health status followed by a 0-100 visual
analogue scale asking respondents to indicate their
overall health state. Health status is converted into a
weighted index by applying preference weights taken
from general population samples. These weights lie
on an index from 0-1 in which 1 represents full
health. The EQ-5D is used widely in studies of peo-
ple with cancer and data is published to support its
reliability and validity (Pickard et al., 2007). It pro-
vides a simple descriptive profile and a single index
value for health status and is recommended for use
in cost-effectiveness analyses.
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Pre-existing factors
For pre-existing factors we will collect socio-demographic
details such as age; gender; marital and social status; ethni-
city; living and work status. Socio-demographics which are
constant, such as gender, will only be asked on one occa-
sion, while others will be included in repeat question-
naires. Comorbid illnesses and other major life events
(The List of Threatening Experiences [34] will also be
collected.
Personal factors
• The Illness Perception Questionnaire-Revised [35]
measures beliefs about illness. Confidence to manage
illness, or self-efficacy, will be measured using Lorig’s
Self Efficacy for Managing Chronic Disease [36], a 6
item scale assessing confidence to measure several
items relating to chronic disease. A mean score of the
items is calculated ranging from 1-10. The scale has
been used in several studies measuring self-efficacy in
people with cancer [37,38].
• The International Positive and Negative Affect Sche-
dule Short Form (PANAS) [39] will be used to con-
sider whether a positive or negative approach to life
affects recover of wellbeing. The 10 question instru-
ment consists of two 5-item mood scales, one designed
to measure positive affect (PA) and the other focusing
on negative affect (NA). The PANAS has been found
to be a reliable and valid instrument [40] and has been
used in cancer populations [41,42].
• The Center for Epidemiological Studies Depression
Scale (CES-D) [43] contains 20 questions asking
respondents how often they have experienced depres-
sive symptoms. Total scores range from 0 to 60 with
high scores indicating high levels of distress. A score ≥
16 suggests a clinically significant level of psychological
distress. The scale has been established as a reliable
and valid instrument for measuring depressive symp-
toms in people with cancer [44] and has been used in
several studies of this population [45,46].
• The State Trait Anxiety Inventory (STAI) [47] is a
40 item assessment which measures trait and state
anxiety separately. Scores range from 20 to 80 and
higher scores indicate higher levels of anxiety.
Environmental factors
External influencing factors will be measured by the Medi-
cal Outcomes Study social support survey (MOS) [48] as
well as access to services, which can be identified through
postcode. The survey instrument consists of 19 questions
concerning the frequency of availability of different types
of support. A higher score for an individual scale or for
Figure 2 Matrix of measures to be used in CREW cohort.
Fenlon et al. BMC Health Services Research 2012, 12:90
http://www.biomedcentral.com/1472-6963/12/90
Page 5 of 8
the overall support index indicates more support available.
Scale and overall scores are converted to a 0-100 value.
This survey has been tested for validity and reliability
among people with chronic illness [48] and has been used
previously by people with cancer [49].
Coping and self-management
Coping appraisal and coping strategies will be assessed by
Carver’s Brief COPE [50]. This 28 item questionnaire is
organised into 14 pairs representing different coping tech-
niques. Participants are given a score from 2 to 8 for each
subscale which represents how frequently they use a parti-
cular method of coping. The questionnaire has been used
in several assessments of coping styles among people with
cancer [51,52], and a recent study has suggested it to be a
valid and reliable instrument [53].
Data collection
Baseline data will be collected prior to surgery. Date of
surgery will be assigned as time 0. Outcome data will be
collected at 5 time points: baseline (prior to initial sur-
gery); time 1, 3 months after study entry (to monitor early
adaptation and coping in those who have surgery only and
detect initial treatment effects for those undergoing adju-
vant chemotherapy); time 2, 9 months after surgery (those
with adjuvant treatment will be completing treatment,
those with surgery only may have made further progress
in recovery); time 3, 15 months after surgery (those having
adjuvant therapy will be in early stages of recovery); and
time 4, 2 years after surgery, to assess longer term implica-
tions. Baseline data will be collected by direct approach
from the recruiting clinician/research nurse. All other
questionnaires will be mailed out to participants.
Bias
Measures to reduce bias on selection include identifying
eligible patients through a systematic screening process
using a standardised procedure. In order to assess poten-
tial non-response bias, non-identifiable socio-demographic
data (with consent) will be collected (age, gender, ethni-
city, marital status, and occupation) on those who choose
not to participate in the study. Where possible any reasons
for non-participation will be gathered.
The questionnaire data will be self-rated, thus reducing
observer bias. This will be piloted for the first three
months in one centre. Strenuous efforts will be made to
reduce missing data and maintain subjects in the cohort.
These include GP checks to ensure patients have not
moved or died, repeat questionnaires being mailed on
non-response and phone calls made for missing data.
Study size
Our sample size calculation is based on the primary out-
come measure (QLACS). The mean generic summary
score for QLACS is 71.2 (SD 25.6) [29]. A difference of
one half a standard deviation is often quoted as a mini-
mum clinically important difference in sample size calcula-
tions: using 80% power to detect a difference of one half of
a standard deviation at the 0.05 significance level we
require 46 cases in the smaller of the groups and 103 in
the larger of the groups to be compared (total 149). Allow-
ing for 30% drop-out inflates this figure to 213 [15,54]. We
intend to use 25 centres, each of which will recruit an
average of 40 cases. Assuming an intra-cluster correlation
of 0.05 the cluster correction increases this figure to 628.
We will look for a difference of one half a standard devia-
tion for all other continuous variables and this sample size
will therefore be appropriate for these variables. We have
chosen to increase the sample size to 1000 cases as this
will allow analysis of rarer groups.
Analysis
For objective 1 descriptive statistics of QLACS will be used
to describe changing health and wellbeing over time. We
will compare this with PWI to compare this population
with healthy norms and EQ5D to compare with other
chronic illness populations. We will examine recurrence
rates and survival curves. For objective 2 descriptive statis-
tics of the SCNS will be used to describe changing health
needs over time and comparisons made with health and
wellbeing status. For objective 3 we will construct regres-
sion models to explore relationships between the recovery
of health and wellbeing and factors that might influence
this, such as the cancer, cancer treatments and symptom
burden (EORTC QLQ-C30 + CR29), social support
(MOS), personal dispositions (IPQR, PANAS and STAI),
self-efficacy (Lorig), self-management (COPE), comorbid-
ities and utilisation of health services. We will then
sequence the regression models and construct graphical
chain models to explore the varying contribution of all our
variables. This will allow us to determine the most impor-
tant factors influencing health and wellbeing outcomes
and determine those most at risk of poor or protracted
recovery. For objective 4 we will use descriptive statistics
to demonstrate how patients access health care services
over time and construct logistic regression models to
explore how this relates to the recovery of health and well-
being. For objective 5 we will describe patients’ coping
strategies using COPE, their confidence to self-manage
problems using Lorig’s self-efficacy scale and construct
logistic regression models to explore how this relates to
the recovery of health and wellbeing. Participants with
missing data will be included in analyses for time points
for which they provide data.
Study organisation and management
The research team and wider study advisory committee
(SAC) includes lay experience of cancer and professional
expertise in psychosocial oncology research, clinical
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oncology, nursing, data management, statistics and epi-
demiology. The conduct and progress of the study will
be discussed and reviewed in study management meet-
ings (SMG) fortnightly for the first six months and
monthly thereafter. The SMG group will consist of the
day-to-day research team and chief investigator. The
SAC will meet at the beginning of the study and
annually thereafter. The study is included in the
National Institute for Health Research (NIHR) Clinical
Research Network (CRN) Portfolio, and we will provide
monthly anonymised reports on study accrual to the
NIHR CRN office. We will also provide regular reports
on study recruitment and progress to the colorectal and
psychosocial National Cancer Research Institute clinical
studies groups.
Discussion
While much data are collected on people with colorectal
cancer, the full picture of their recovery of health and well-
being has not been captured. This study will address this
issue, reporting a wide range of personal, social and physi-
cal attributes that might affect people’s recovery of health
following cancer. It will also give people with colorectal
cancer a systematic way to record their personal perspec-
tive on the issues that affect them over a period of 2 years
following surgery. Once established the cohort can be fol-
lowed up for longer periods and be approached to partici-
pate in related projects as appropriate and subject to
funding.
A weakness of the study is that it is not possible to gain
a baseline of health prior to cancer diagnosis; the closest
to baseline that can be established therefore is prior to
cancer treatment. The time immediately prior to surgery
has been chosen to represent baseline for a number of rea-
sons: most people will not have had any cancer treatment
at this time; most people will have had a number of
planned investigations and so will be some time post diag-
nosis; this is a single entry point where all eligible people
can be identified for inclusion in the study. Nevertheless,
some people will still be too distressed, sick or frail to par-
ticipate in the study. In order to account for this we have
introduced a reduced level of consent so that some data is
captured on this group.
This study will provide a powerful tool for understand-
ing the process of recovery following diagnosis and treat-
ment for cancer, to understand what factors aid or hinder
people’s recovery and provide evidence from which appro-
priate interventions can be developed to enhance the lives
of people with cancer.
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